All-trans retinoic acid induces monocyte growth factor receptor (c-fms) gene expression in HL-60 leukemia cells.

Abstract:

:All-trans-retinoic (ATRA) treatment of patients with acute promyelocytic leukemia results in differentiation of the malignant cells and a high complete remission rate. ATRA treatment induced granulocytic differentiation in HL-60 cells as assessed by nitroblue tetrazolium (NBT) reduction, but had no effect on non-specific esterase (NSE) straining, as expected in cells maturing along the monocytic lineage. However, our results demonstrate that ATRA (0.1-10 microM) induces expression of the c-fms (monocyte colony-stimulating factor receptor) gene in HL-60 cells. This effect was detectable after 2 days and expression was maximal at 5 days. Similar results were obtained during treatment with cis-retinoic acid (CRA), hexamethylene bisacetamide (HMBA), or dimethyl sulfoxide (DMSO). The results also demonstrate that ATRA-induced c-fms expression is potentiated by exposure to tumor necrosis factor alpha (TNF alpha) or dibutyryl cyclic adenosine monophosphate (cAMP). The induction of c-fms transcripts by ATRA is associated with induction of M-CSF-binding ability, suggesting cell surface expression of the monocyte growth factor receptor. Our results indicate that retinoic acid can induce features of both monocytic and granulocytic differentiation in HL-60 cells.

journal_name

Leukemia

journal_title

Leukemia

authors

Hsu HC,Yang K,Kharbanda S,Clinton S,Datta R,Stone RM

subject

Has Abstract

pub_date

1993-03-01 00:00:00

pages

458-62

issue

3

eissn

0887-6924

issn

1476-5551

journal_volume

7

pub_type

杂志文章

相关文献

LEUKEMIA文献大全
  • SP/drug efflux functionality of hematopoietic progenitors is controlled by mesenchymal niche through VLA-4/CD44 axis.

    abstract::Hematopoiesis is orchestrated by interactions between hematopoietic stem/progenitor cells (HSPCs) and stromal cells within bone marrow (BM) niches. Side population (SP) functionality is a major characteristic of HSPCs related to quiescence and resistance to drugs and environmental stresses. At steady state, SP cells a...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2013.256

    authors: Malfuson JV,Boutin L,Clay D,Thépenier C,Desterke C,Torossian F,Guerton B,Anginot A,de Revel T,Lataillade JJ,Le Bousse-Kerdilès MC

    更新日期:2014-04-01 00:00:00

  • Treatment of neutropenia-related fungal infections with granulocyte colony-stimulating factor-elicited white blood cell transfusions: a pilot study.

    abstract::Neutropenia-related fungal infections can be life-threatening despite antifungal therapy. We evaluated the role of recombinant granulocyte colony-stimulating factor (rG-CSF)-elicited white blood cell (WBC) transfusions in patients with neutropenia-related fungal infections. Adult patients with hematologic malignancies...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.leu.2400811

    authors: Dignani MC,Anaissie EJ,Hester JP,O'Brien S,Vartivarian SE,Rex JH,Kantarjian H,Jendiroba DB,Lichtiger B,Andersson BS,Freireich EJ

    更新日期:1997-10-01 00:00:00

  • Proteomic analysis of childhood leukemia.

    abstract::Childhood acute lymphoblastic and myeloid leukemias are stratified into molecular and cytogenetic subgroups important for prognosis and therapy. Studies have shown that gene expression profiles can discriminate between leukemia subtypes. Thus, proteome analysis similarly holds the potential for characterizing differen...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.leu.2403897

    authors: Hegedus CM,Gunn L,Skibola CF,Zhang L,Shiao R,Fu S,Dalmasso EA,Metayer C,Dahl GV,Buffler PA,Smith MT

    更新日期:2005-10-01 00:00:00

  • Increased levels of interleukin-6 (IL-6) in serum and spontaneous in vitro production of IL-6 by lymph node mononuclear cells of patients with angio-immunoblastic lymphadenopathy with dysproteinemia (AILD), and clinical effectiveness of cyclosporin A.

    abstract::Serum levels of cytokines and in vitro cytokine production by lymph node mononuclear cells (LNMC) were studied in four patients with angio-immunoblastic lymphadenopathy with dysproteinemia (AILD) or AILD-type T cell lymphoma. An increased level of serum interleukin-6 (IL-6) was detected on initial diagnosis in both of...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Yamamura M,Honda M,Yamada Y,Itoyama T,Sohda H,Yubashi T,Momita S,Kamihira S,Ohmoto Y,Tomonaga M

    更新日期:1996-09-01 00:00:00

  • In vitro responsiveness to interleukins and theophylline of CD16+, CD56- natural killer cells in a patient with chronic granular lymphocyte disorder.

    abstract::We report here the case of a 55-year-old patient with chronic granular lymphocyte disorder associated with moderate neutropenia. The majority of peripheral blood lymphocytes displayed a CD3-, CD8-, CD16+, CD56(NKH1)- phenotype. The patient's cells showed high spontaneous cytotoxic activity against K562 targets and dev...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Bayle C,Vitté-Mony I,Lang P,Pico J,Hercend T,Bertoglio J

    更新日期:1992-05-01 00:00:00

  • Intensive chemotherapy in childhood myelodysplastic syndrome. A comparison with results in acute myeloid leukemia.

    abstract::Myelodysplastic syndrome (MDS) in children is often considered as a variant of acute myeloid leukemia (AML) and frequently treated as such. However, there are very few reported data on the outcome following AML treatment. We analyzed 20 consecutive cases of de novo MDS treated in Denmark according to the NOPHO AML pro...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章

    doi:

    authors: Hasle H,Kerndrup G,Yssing M,Clausen N,Ostergaard E,Jacobsen N,Jacobsen BB

    更新日期:1996-08-01 00:00:00

  • Enasidenib, an inhibitor of mutant IDH2 proteins, induces durable remissions in older patients with newly diagnosed acute myeloid leukemia.

    abstract::Older adults with acute myeloid leukemia (AML) who are not fit for standard chemotherapy historically have poor outcomes. Approximately 12-15% of older patients with AML harbor isocitrate dehydrogenase 2 (IDH2) gene mutations. Enasidenib is an oral inhibitor of mutant IDH2 proteins. Among 39 patients with newly diagno...

    journal_title:Leukemia

    pub_type: 杂志文章,多中心研究

    doi:10.1038/s41375-019-0472-2

    authors: Pollyea DA,Tallman MS,de Botton S,Kantarjian HM,Collins R,Stein AS,Frattini MG,Xu Q,Tosolini A,See WL,MacBeth KJ,Agresta SV,Attar EC,DiNardo CD,Stein EM

    更新日期:2019-11-01 00:00:00

  • Early relapse following initial therapy for multiple myeloma predicts poor outcomes in the era of novel agents.

    abstract::Outcomes for patients with multiple myeloma (MM) have improved in recent years owing to use of novel agents and high-dose therapy followed by autologous stem cell transplant (ASCT). We analyzed the outcomes of 511 consecutive patients treated with novel therapies at our institution between 2006 and 2014 to determine t...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.147

    authors: Majithia N,Rajkumar SV,Lacy MQ,Buadi FK,Dispenzieri A,Gertz MA,Hayman SR,Dingli D,Kapoor P,Hwa L,Lust JA,Russell SJ,Go RS,Kyle RA,Kumar SK

    更新日期:2016-11-01 00:00:00

  • Relation between genetic variants of the ataxia telangiectasia-mutated (ATM) gene, drug resistance, clinical outcome and predisposition to childhood T-lineage acute lymphoblastic leukaemia.

    abstract::The T-lineage phenotype in children with acute lymphoblastic leukaemia (ALL) is associated with in vitro drug resistance and a higher relapse-risk compared to a precursor B phenotype. Our study was aimed to investigate whether mutations in the ATM gene occur in childhood T-lineage acute lymphoblastic leukaemia (T-ALL)...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403943

    authors: Meier M,den Boer ML,Hall AG,Irving JA,Passier M,Minto L,van Wering ER,Janka-Schaub GE,Pieters R

    更新日期:2005-11-01 00:00:00

  • Pomalidomide, bortezomib and low-dose dexamethasone in lenalidomide-refractory and proteasome inhibitor-exposed myeloma.

    abstract::This phase 1 dose-escalation study evaluated pomalidomide, bortezomib (subcutaneous (SC) or intravenous (IV)) and low-dose dexamethasone (LoDEX) in lenalidomide-refractory and proteasome inhibitor-exposed relapsed or relapsed and refractory multiple myeloma (RRMM). In 21-day cycles, patients received pomalidomide (1-4...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2017.173

    authors: Richardson PG,Hofmeister CC,Raje NS,Siegel DS,Lonial S,Laubach J,Efebera YA,Vesole DH,Nooka AK,Rosenblatt J,Doss D,Zaki MH,Bensmaine A,Herring J,Li Y,Watkins L,Chen MS,Anderson KC

    更新日期:2017-12-01 00:00:00

  • Allogeneic hematopoietic cell transplantation for multiple myeloma in Europe: trends and outcomes over 25 years. A study by the EBMT Chronic Malignancies Working Party.

    abstract::We describe the use and outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for multiple myeloma (MM) in Europe between January 1990 and December 2012. We identified 7333 patients, median age at allo-HSCT was 51 years (range: 18-78), of whom 4539 (62%) were males. We distinguished three groups: ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2016.101

    authors: Sobh M,Michallet M,Gahrton G,Iacobelli S,van Biezen A,Schönland S,Petersen E,Schaap N,Bonifazi F,Volin L,Meijer E,Niederwieser D,El Cheikh J,Tabrizi R,Fegeux N,Finke J,Bunjes D,Cornelissen J,Einsele H,Bruno B,Pott

    更新日期:2016-10-01 00:00:00

  • Polyclonal expansion of T-cell receptor-gamma delta+ T lymphocytes associated with neutropenia and thrombocytopenia.

    abstract::A patient with large granular lymphocyte (LGL) expansion (T-gamma lymphocytosis), neutropenia and thrombocytopenia was studied longitudinally. Analysis of peripheral blood mononuclear cells (PBMC) demonstrated an unusual large proportion of CD3+ T-lymphocytes expressing a gamma delta T-cell receptor (TcR-gamma delta)....

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: van Oostveen JW,Breit TM,de Wolf JT,Brandt RM,Smit JW,van Dongen JJ,Borst J,Melief CJ

    更新日期:1992-05-01 00:00:00

  • Aplidine, a new anticancer agent of marine origin, inhibits vascular endothelial growth factor (VEGF) secretion and blocks VEGF-VEGFR-1 (flt-1) autocrine loop in human leukemia cells MOLT-4.

    abstract::The mechanism by which aplidine, a marine natural product in early clinical development as an anticancer agent, induces cell growth inhibition and apoptosis has been investigated in the human leukemia cell line MOLT-4. This cell line is characterized not only by the ability to secrete VEGF, but also for the presence o...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402788

    authors: Broggini M,Marchini SV,Galliera E,Borsotti P,Taraboletti G,Erba E,Sironi M,Jimeno J,Faircloth GT,Giavazzi R,D'Incalci M

    更新日期:2003-01-01 00:00:00

  • Potential involvement of the AML1-MTG8 fusion protein in the granulocytic maturation characteristic of the t(8;21) acute myelogenous leukemia revealed by microarray analysis.

    abstract::The AML1 (RUNX1)-MTG8 (ETO) fusion transcription factor generated by the t(8;21) translocation is believed to deregulate the expression of genes that are crucial for normal differentiation and proliferation of hematopoietic progenitors, resulting in acute myelogenous leukemia. To elucidate the role of AML1-MTG8 in leu...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2402465

    authors: Shimada H,Ichikawa H,Ohki M

    更新日期:2002-05-01 00:00:00

  • A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.

    abstract::Myelofibrosis (MF; primary or post-essential thrombocythemia/polycythemia vera) is incurable clonal myeloproliferative disorder, with no effective treatment. Epigenetic changes play an important role in cancer pathogenesis through transcriptional silencing of critical tumor suppressor genes. We conducted a phase-II st...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2008.91

    authors: Quintás-Cardama A,Tong W,Kantarjian H,Thomas D,Ravandi F,Kornblau S,Manshouri T,Cortes JE,Garcia-Manero G,Verstovsek S

    更新日期:2008-05-01 00:00:00

  • PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia.

    abstract::Chronic lymphocytic leukemia (CLL) cells with aggressive clinical properties express lipoprotein lipase (LPL), which generates activating ligands for the nuclear receptor peroxisome proliferator activated receptor (PPAR)α and allows fatty acids to be used as fuel. However, the role of PPARα in CLL is unclear. PPARα wa...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2012.329

    authors: Spaner DE,Lee E,Shi Y,Wen F,Li Y,Tung S,McCaw L,Wong K,Gary-Gouy H,Dalloul A,Ceddia R,Gorzcynski R

    更新日期:2013-04-01 00:00:00

  • Rearrangement of the retinoic acid receptor gene in acute promyelocytic leukemia.

    abstract::The retinoic acid receptor-alpha (RAR-alpha) gene was previously localized to chromosome 17q21, a region close to the t(15;17) (q22;q21) abnormality in acute promyelocytic leukemia (APL). We used the RAR-alpha gene as a probe and found that eight of nine APL patient samples with t(15;17) (q22;q21) showed rearranged ba...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Chang KS,Trujillo JM,Ogura T,Castiglione CM,Kidd KK,Zhao SR,Freireich EJ,Stass SA

    更新日期:1991-03-01 00:00:00

  • Myeloid to lymphoid clonal succession following autologous transplantation in second chronic phase of chronic myeloid leukaemia.

    abstract::A 23-year-old male found to have Philadelphia chromosome-positive chronic myeloid leukemia (CML) in May 1987 suffered a myeloid blastic transformation in April 1993. A second chronic phase was achieved after treatment with daunorubicin and cytosine arabinoside and the patient then underwent autologous bone marrow tran...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Spencer A,Vulliamy T,Chase A,Goldman JM

    更新日期:1995-12-01 00:00:00

  • Cytogenetic studies of infant acute lymphoblastic leukemia: poor prognosis of infants with t(4;11) - a report of the Children's Cancer Group.

    abstract::Infants less than 1 year of age at diagnosis of acute lymphoblastic leukemia (ALL) have a poor prognosis, which has been attributed primarily to a breakpoint in chromosomal band 11q23 or the MLL gene. Most infants with an 11q23 breakpoint have a t(4;11)(q21 ;q23). We studied the cytogenetics of the leukemia cells of 5...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2401413

    authors: Heerema NA,Sather HN,Ge J,Arthur DC,Hilden JM,Trigg ME,Reaman GH

    更新日期:1999-05-01 00:00:00

  • Specific point mutations that activate v-abl are not found in Philadelphia-negative chronic myeloid leukaemia, Philadelphia-negative acute lymphoblastic leukaemia or blast transformation of chronic myeloid leukaemia.

    abstract::The involvement of the BCRlABL fusion gene in patients with Philadelphia (Ph) chromosome positive chronic myeloid leukaemia (CML) and acute lymphoblastic leukaemia (ALL) is well characterised, but the molecular events underlying the cases of Ph-negative CML and ALL that lack BCR gene involvement and those that cause t...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Melo JV,Goldman JM

    更新日期:1992-08-01 00:00:00

  • BCL-2 family proteins as 5-Azacytidine-sensitizing targets and determinants of response in myeloid malignancies.

    abstract::Synergistic molecular vulnerabilities enhancing hypomethylating agents in myeloid malignancies have remained elusive. RNA-interference drug modifier screens identified antiapoptotic BCL-2 family members as potent 5-Azacytidine-sensitizing targets. In further dissecting BCL-XL, BCL-2 and MCL-1 contribution to 5-Azacyti...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2014.44

    authors: Bogenberger JM,Kornblau SM,Pierceall WE,Lena R,Chow D,Shi CX,Mantei J,Ahmann G,Gonzales IM,Choudhary A,Valdez R,Camoriano J,Fauble V,Tiedemann RE,Qiu YH,Coombes KR,Cardone M,Braggio E,Yin H,Azorsa DO,Mesa RA,Ste

    更新日期:2014-08-01 00:00:00

  • BCL2 mutations in diffuse large B-cell lymphoma.

    abstract::BCL2 is deregulated in diffuse large B-cell lymphoma (DLBCL) by the t(14;18) translocation, gene amplification and/or nuclear factor-κB signaling. RNA-seq data have recently shown that BCL2 is the most highly mutated gene in germinal center B-cell (GCB) DLBCL. We have sequenced BCL2 in 298 primary DLBCL biopsies, 131 ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/leu.2011.378

    authors: Schuetz JM,Johnson NA,Morin RD,Scott DW,Tan K,Ben-Nierah S,Boyle M,Slack GW,Marra MA,Connors JM,Brooks-Wilson AR,Gascoyne RD

    更新日期:2012-06-01 00:00:00

  • Inducible production of macrophage colony-stimulating factor (CSF-1) by malignant and normal human T cells.

    abstract::The CEM-ON malignant T cell line and long-term cultured normal T cells can be induced to release CSF-1 in their culture supernatants. Chemical inducers (PMA + A23187) and, more interestingly, cytokines (tumor necrosis factor alpha (TNF alpha) and interleukin-1 alpha (IL-1 alpha)), as well as physiological (antigen + I...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Praloran V,Gascan H,Papin S,Chevalier S,Trossaërt M,Boursier MC

    更新日期:1990-06-01 00:00:00

  • Role of DNA methylation for expression of novel stem cell marker CDCP1 in hematopoietic cells.

    abstract::CDCP1, a novel stem cell marker, is expressed in hematopoietic cell line K562 but not in Jurkat. When CDCP1 promoter was transfected exogenously, Jurkat showed comparable promoter activity with K562, suggesting that the factor to enhance transcription was present but interfered to function in Jurkat. The reporter assa...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2404312

    authors: Kimura H,Morii E,Ikeda JI,Ezoe S,Xu JX,Nakamichi N,Tomita Y,Shibayama H,Kanakura Y,Aozasa K

    更新日期:2006-09-01 00:00:00

  • Prevention of T-cell lymphoma in AKR/J mice.

    abstract::Injection of a dual tropic virus (DTV) isolated from a T cell lymphoma AKR/J mice into the thymus of 14 day old AKR/J puppies accelerates lymphoma development; 90-100% of the injected mice develop the disease within 120 days. In contrast a cell free centrifuge CFC-666 prepared B cell lymphoma of AKR/J origin injected ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Peled A,Haran-Ghera N

    更新日期:1988-12-01 00:00:00

  • Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV.

    abstract::Major molecular remission (MMR) is an important therapy goal in chronic myeloid leukemia (CML). So far, MMR is not a failure criterion according to ELN management recommendation leading to uncertainties when to change therapy in CML patients not reaching MMR after 12 months. At monthly landmarks, for different molecul...

    journal_title:Leukemia

    pub_type: 杂志文章,随机对照试验

    doi:10.1038/s41375-018-0055-7

    authors: Saussele S,Hehlmann R,Fabarius A,Jeromin S,Proetel U,Rinaldetti S,Kohlbrenner K,Einsele H,Falge C,Kanz L,Neubauer A,Kneba M,Stegelmann F,Pfreundschuh M,Waller CF,Oppliger Leibundgut E,Heim D,Krause SW,Hofmann WK,Has

    更新日期:2018-05-01 00:00:00

  • Alternative rearrangements of immunoglobulin light chain genes in human leukemia.

    abstract::Immunoglobulin heavy and light chain genes undergo rearrangement before they can be expressed by B-cells. A sequence of successive rearrangements has been proposed, suggesting that these events are initiated on heavy chain genes and are followed by sequential attempts of light chain gene rearrangements involving kappa...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Tang JQ,Béné MC,Faure GC

    更新日期:1991-08-01 00:00:00

  • NOTCH1 and FBXW7 mutations have a favorable impact on early response to treatment, but not on outcome, in children with T-cell acute lymphoblastic leukemia (T-ALL) treated on EORTC trials 58881 and 58951.

    abstract::Risk-adjusted treatment stratification in T-cell acute lymphoblastic leukemias (T-ALLs) is currently based only on early response to chemotherapy. We investigated the prognostic implication of hyperactivation of NOTCH pathway resulting from mutations of NOTCH1 or FBXW7 in children with T-ALL enrolled in EORTC-CLG tria...

    journal_title:Leukemia

    pub_type: 临床试验,杂志文章,多中心研究

    doi:10.1038/leu.2010.205

    authors: Clappier E,Collette S,Grardel N,Girard S,Suarez L,Brunie G,Kaltenbach S,Yakouben K,Mazingue F,Robert A,Boutard P,Plantaz D,Rohrlich P,van Vlierberghe P,Preudhomme C,Otten J,Speleman F,Dastugue N,Suciu S,Benoit Y,B

    更新日期:2010-12-01 00:00:00

  • VEGF receptors on chronic lymphocytic leukemia (CLL) B cells interact with STAT 1 and 3: implication for apoptosis resistance.

    abstract::We have previously shown that chronic lymphocytic leukemia (CLL) B cells secrete vascular endothelial growth factor (VEGF) in vitro, have constitutively active VEGF receptors R1 and R2, and respond to exogenous VEGF by specifically upregulating Mcl-1 and XIAP in association with decreased cell death. We found that epi...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:10.1038/sj.leu.2403667

    authors: Lee YK,Shanafelt TD,Bone ND,Strege AK,Jelinek DF,Kay NE

    更新日期:2005-04-01 00:00:00

  • De novo AML with dysplastic hematopoiesis: cytogenetic and prognostic significance.

    abstract::Dysplastic hematopoiesis is the morphological hallmark of myelodysplastic syndromes. Dysplastic features in one or more lineages are also found frequently in bone marrow aspirates from patients with de novo AML and have been associated with an unfavorable prognosis. We asked whether dyshematopoiesis is an independent ...

    journal_title:Leukemia

    pub_type: 杂志文章

    doi:

    authors: Gahn B,Haase D,Unterhalt M,Drescher M,Schoch C,Fonatsch C,Terstappen LW,Hiddemann W,Büchner T,Bennett JM,Wörmann B

    更新日期:1996-06-01 00:00:00